<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48518">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474589</url>
  </required_header>
  <id_info>
    <org_study_id>SIGA-246-008</org_study_id>
    <nct_id>NCT02474589</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat</brief_title>
  <acronym>SIGA246-008</acronym>
  <official_title>An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SIGA Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>SIGA Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and
      tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics and safety and tolerability data will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2015</start_date>
  <completion_date type="Actual">August 24, 2016</completion_date>
  <primary_completion_date type="Actual">August 24, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the number of participants with Adverse Events</measure>
    <time_frame>45 days</time_frame>
    <description>To determine the safety and tolerability of oral tecovirimat</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">422</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tecovirimat</intervention_name>
    <description>Study is based on Animal Regulatory Rule</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>ST-246</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Does not apply</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 80 years old, inclusive

          -  Available for clinical follow-up for the duration of the study

          -  Able and willing to give informed consent

          -  In good general health without clinically significant medical history; not have been
             hospitalized for a chronic medical condition for the last 2 years

          -  Able to comply with dietary requirements throughout the study drug dosing period

          -  Adequate venous access for those individuals participating in PK testing

          -  PE and laboratory results without clinically significant findings within the 14 days
             before receipt of study drug

          -  Agree not to drink alcohol from the beginning of the Screening Period through the
             completion of the Day 28 Follow up Visit

          -  Agree not to use any nicotine products, including electronic vapor cigarettes,
             nicotine patches or nicotine gum for at least 30 days before the Day 1 Visit and
             through completion of the Day 15 Dosing complete Visit

          -  Agree not to consume caffeine during all study visits, including overnight stays if
             participating in PK subset

          -  Agree not to receive any immunizations/vaccinations

          -  Agree not to take herbal products

          -  Able and willing to refrain from taking any prescriptions and nonprescription
             medications with exceptions

          -  For women of childbearing potential, negative serum and urine pregnancy testing

          -  If male, agree not to donate sperm

          -  Meet 1 of the following criteria: The subject or their partner has undergone surgical
             sterilization; the subject is postmenopausal; the subject agrees to be abstinent; the
             subject agrees to consistently use a method of approved birth control.

        Exclusion Criteria:

          -  Pregnant or breast-feeding or planning pregnancy

          -  Have a history of any clinically significant conditions

          -  Have any limitation of activity related to cardiac disease

          -  Have a bleeding disorder diagnosed by a doctor, or a history of significant bruising
             or bleeding with intramuscular injections or blood draws

          -  Currently using certain medications

          -  Have a malignancy that is active or a treated malignancy for which there is no
             reasonable assurance of sustained cure, or malignancy that is likely to recur during
             the study

          -  Have a history of seizure

          -  Have a clinically significant blood dyscrasia

          -  Have a history of drug allergy that contraindicates participation in the trial

          -  Have a medical, psychiatric, or social condition or any occupational reason, or other
             responsibility that in the judgment of the investigator would render the subject
             unable to comply with the protocol

          -  Have an inability to swallow medication

          -  Have a clinically significant abnormal ECG

          -  Have participated in a clinical trials within 30 days of study entry or planning to
             participate in any experimental treatment study during the study period

          -  Have a history or current drug or alcohol abuse

          -  Have received immunizations/vaccines

          -  Have a current clinically significant acute bacterial, fungal, or mycobacterial
             infection requiring administration of systemic antibiotics

          -  Have known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal
             infection with the exception of clinically significant dermal infections

          -  Have known hepatitis B or C infection, or positive test result

          -  Have known HIV infection or AIDS or a positive test for HIV

          -  Have a current clinically significant viral infection

          -  Have known clinically significant chronic viral infection

          -  have received treatment with greater than 20 mg prednisone or equivalent dose or any
             immunosuppressant or immunomodulary medication

          -  Have abnormal laboratory testing during screening

          -  Have a greater than or equal than 20% risk of suffering a major cardiovascular event

          -  Have been previously enrolled in this or any clinical trial involving tecovirimat
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Hruby, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>SIGA Technologies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paradigm Research</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paradigm Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clinical Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research LLC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>June 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>orthopoxvirus</keyword>
  <keyword>smallpox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
